Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker
Authors:
- 14 October 2025
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 1-9
Abstract
Objectives Rapid Early Progression (REP) in glioblastoma occurs when there is tumor growth between the immediate postoperative MRI and the radiotherapy planning MRI. We reviewed a large multicenter series to determine the frequency, predictors, and impact of REP. Methods Patients treated with radiotherapy for newly-diagnosed glioblastoma between 2014 and 2023 were reviewed. Preoperative/postoperative MRIs were individually reviewed to determine radiographic extent of resection (EOR) as either gross-total (GTR), near-total (NTR), subtotal (STR), or biopsy. Radiotherapy-planning MRIs were evaluated for REP and classified as clear, mild, or none; and REP location as local, distant, or both. Progression-free survival (PFS), overall survival (OS), and predictors for REP were analyzed and compared. Results Four hundred and one (401) patients met inclusion criteria. REP was seen in 62.1% of patients. Compared to patients with GTR, increased REP was seen in patients with NTR (OR = 7.94, p < 0.001), STR (OR = 15.12, p < 0.001), and biopsy (OR = 6.52, p < 0.001). Time from resection to radiotherapy-planning MRI was not associated with REP (p = 0.611). REP predicted inferior PFS (p = 0.011) with further decrease seen in clear REP (HR = 1.713, 95% CI: 1.202–2.441) as compared to mild REP (HR = 1.511, 95% CI: 1.046–2.183). Conclusion These data support REP as a common and practical biomarker suggestive of more aggressive tumor phenotype. REP was strongly associated with EOR (although not with delays to radiotherapy) and associated with decreased PFS. Novel strategies are needed to integrate REP into clinical trial stratification, predict for REP a priori, reduce its frequency, and/or tailor adjuvant therapy.Keywords
This publication has 18 references indexed in Scilit:
- Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysisNeuro-Oncology Advances, 2022
- Rapid Early Tumor Progression is Prognostic in Glioblastoma PatientsAmerican Journal of Clinical Oncology, 2019
- Investigating the Ketogenic Diet As Treatment for Primary Aggressive Brain Cancer: Challenges and Lessons LearnedFrontiers in Nutrition, 2018
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsClinical Cancer Research, 2017
- Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomesJournal of Neuro-Oncology, 2017
- Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapyJournal of Neuro-Oncology, 2017
- Early postoperative tumor progression predicts clinical outcome in glioblastoma—implication for clinical trialsJournal of Neuro-Oncology, 2017
- Association of the Extent of Resection With Survival in GlioblastomaJAMA Oncology, 2016
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005